A Tool to Change Human Antigen R Protein Expression: May Have Implications in both Cancer & Diabetes >


Copyright © 2014 by Dr. Kerry Masterson  ·  All Rights reserved  ·  E-Mail: km@humanantigenr.com

  HuR: A Cancer and Diabetes Target          HuR mRNA Protective Sequence (HPS)           HPS Experiment Results          Contact
Human Antigen R mRNA Protective Sequence Site
PubMed search for HuR and Breast Cancer

1: Chua CE, Tang BL. The role of the small GTPase Rab31 in cancer. J Cell Mol Med. 2014 Dec 3. doi: 10.1111/jcmm.12403. [Epub ahead of print] PubMed PMID:25472813.

2: Luo NA, Qu YQ, Yang GD, Wang T, Li RL, Jia LT, Dong R. Post-transcriptional up-regulation of PDGF-C by HuR in advanced and stressed breast cancer. Int J Mol Sci. 2014 Nov 6;15(11):20306-20. doi: 10.3390/ijms151120306. PubMed PMID:
25383675; PubMed Central PMCID: PMC4264168.

3: Yasuda M, Hatanaka T, Shirato H, Nishioka T. Cell type-specific reciprocal regulation of HIF1A gene expression is dependent on 5'- and 3'-UTRs. Biochem Biophys Res Commun. 2014 May 16;447(4):638-43. doi: 10.1016/j.bbrc.2014.04.058.
Epub 2014 Apr 21. PubMed PMID: 24769203.

4: Griseri P, Pagès G. Control of pro-angiogenic cytokine mRNA half-life in cancer: the role of AU-rich elements and associated proteins. J Interferon Cytokine Res. 2014 Apr;34(4):242-54. doi: 10.1089/jir.2013.0140. Review. PubMed PMID: 24697202.

5: Al-Souhibani N, Al-Ghamdi M, Al-Ahmadi W, Khabar KS. Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells. Carcinogenesis. 2014 Sep;35(9):1983-92. doi: 10.1093/carcin/bgu080. Epub 2014 Apr 1.       PubMed PMID: 24692066; PubMed Central PMCID: PMC4146410.

6: Latorre E, Castiglioni I, Gatto P, Carelli S, Quattrone A, Provenzani A. Loss  of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines. J Pharmacol Exp Ther. 2014 Apr;349(1):99-106. doi:
10.1124/jpet.113.211839. Epub 2014 Feb 3. PubMed PMID: 24492650.

7: Krishnan N, Titus MA, Thapar R. The prolyl isomerase pin1 regulates mRNA levels of genes with short half-lives by targeting specific RNA binding proteins. PLoS One. 2014 Jan 9;9(1):e85427. doi: 10.1371/journal.pone.0085427. eCollection
2014. PubMed PMID: 24416409; PubMed Central PMCID: PMC3887067.

8: D'Uva G, Bertoni S, Lauriola M, De Carolis S, Pacilli A, D'Anello L, Santini D, Taffurelli M, Ceccarelli C, Yarden Y, Montanaro L, Bonafé M, Storci G.Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. PLoS One. 2013 Nov 15;8(11):e80742. doi:10.1371/journal.pone.0080742. eCollection 2013. PubMed PMID: 24260469; PubMed Central PMCID: PMC3829939.

9: Yuan L, Xiao Y, Zhou Q, Yuan D, Wu B, Chen G, Zhou J. Proteomic analysis reveals that MAEL, a component of nuage, interacts with stress granule proteins in cancer cells. Oncol Rep. 2014 Jan;31(1):342-50. doi: 10.3892/or.2013.2836.
Epub 2013 Nov 5. PubMed PMID: 24189637.

10: Wang J, Li D, Wang B, Wu Y. Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013 Sep;141(2):213-24.
doi: 10.1007/s10549-013-2679-7. Epub 2013 Sep 14. PubMed PMID: 24036660.

11: Li Y, Yu J, DU D, Fu S, Chen Y, Yu F, Gao P. Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells. Oncol Lett. 2013 Jul;6(1):156-160. Epub 2013 May 17. PubMed PMID: 23946796; PubMed Central PMCID: PMC3742653.

12: Sharma S, Verma S, Vasudevan M, Samanta S, Thakur JK, Kulshreshtha R. The interplay of HuR and miR-3134 in regulation of AU rich transcriptome. RNA Biol. 2013 Aug 1;10(8):1283-90. doi: 10.4161/rna.25482. Epub 2013 Jun 20. PubMed PMID: 23823647; PubMed Central PMCID: PMC3817149.

13: Zhu Z, Wang B, Bi J, Zhang C, Guo Y, Chu H, Liang X, Zhong C, Wang J. Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumour Biol. 2013 Aug;34(4):2299-308. doi:
10.1007/s13277-013-0774-3. Epub 2013 Apr 19. PubMed PMID: 23605320.

14: Yang F, Miao L, Mei Y, Wu M. Retinoic acid-induced HOXA5 expression is co-regulated by HuR and miR-130a. Cell Signal. 2013 Jun;25(6):1476-85. doi: 10.1016/j.cellsig.2013.03.015. Epub 2013 Mar 23. PubMed PMID: 23528537.

15: Al-Ahmadi W, Al-Ghamdi M, Al-Souhibani N, Khabar KS. miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J Pathol. 2013 May;230(1):28-38. doi: 10.1002/path.4178. Epub 2013 Mar
21. PubMed PMID: 23401122; PubMed Central PMCID: PMC3732382.

16: Le Quesne J. UTRly malignant: mRNA stability and the invasive phenotype in breast cancer. J Pathol. 2013 Jun;230(2):129-31. doi: 10.1002/path.4175. Epub 2013 Mar 21. PubMed PMID: 23389914.

17: Hsia TC, Tu CY, Chen YJ, Wei YL, Yu MC, Hsu SC, Tsai SL, Chen WS, Yeh MH, Yen CJ, Yu YL, Huang TC, Huang CY, Hung MC, Huang WC. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction
enhances the aggressiveness of triple-negative breast cancer cells. Mol Pharmacol. 2013 Apr;83(4):857-69. doi: 10.1124/mol.112.082743. Epub 2013 Jan 25. PubMed PMID: 23355539.

18: Yan W, Zhang Y, Zhang J, Cho SJ, Chen X. HuR is necessary for mammary epithelial cell proliferation and polarity at least in part via ΔNp63. PLoS One. 2012;7(9):e45336. doi: 10.1371/journal.pone.0045336. Epub 2012 Sep 18. PubMed
PMID: 23028944; PubMed Central PMCID: PMC3445479.

19: Upadhyay R, Sanduja S, Kaza V, Dixon DA. Genetic polymorphisms in RNA binding proteins contribute to breast cancer survival. Int J Cancer. 2013 Feb 1;132(3):E128-38. doi: 10.1002/ijc.27789. Epub 2012 Sep 18. PubMed PMID:
22907529; PubMed Central PMCID: PMC3508313.

20: Latorre E, Tebaldi T, Viero G, Spartà AM, Quattrone A, Provenzani A. Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Mol Cancer. 2012 Mar 21;11:13. doi: 10.1186/1476-4598-11-13. PubMed
PMID: 22436134; PubMed Central PMCID: PMC3325864.

21: Leucci E, Zriwil A, Gregersen LH, Jensen KT, Obad S, Bellan C, Leoncini L, Kauppinen S, Lund AH. Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene. 2012 Dec 6;31(49):5081-9.
doi: 10.1038/onc.2012.15. Epub 2012 Feb 6. PubMed PMID: 22310293.

22: Gabai VL, Meng L, Kim G, Mills TA, Benjamin IJ, Sherman MY. Heat shock transcription factor Hsf1 is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR. Mol Cell Biol. 2012
Mar;32(5):929-40. doi: 10.1128/MCB.05921-11. Epub 2012 Jan 3. PubMed PMID: 22215620; PubMed Central PMCID: PMC3295200.

23: Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG. Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. Oncol Rep. 2011 Jul;26(1):237-45. doi:
10.3892/or.2011.1271. Epub 2011 Apr 18. PubMed PMID: 21503589.

24: Heinonen M, Hemmes A, Salmenkivi K, Abdelmohsen K, Vilén ST, Laakso M,Leidenius M, Salo T, Hautaniemi S, Gorospe M, Heikkilä P, Haglund C, Ristimäki A. Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J
Pathol. 2011 Aug;224(4):529-39. doi: 10.1002/path.2889. Epub 2011 Apr 11. PubMed PMID: 21480233; PubMed Central PMCID: PMC3504799.

25: Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG. Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis. Anticancer Res. 2011 Jan;31(1):303-10. PubMed PMID: 21273615.

26: Woo HH, Yi X, Lamb T, Menzl I, Baker T, Shapiro DJ, Chambers SK. Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer. Mol Cell Biol. 2011 Jan;31(1):215-25. doi: 10.1128/MCB.01031-10.
Epub 2010 Oct 25. PubMed PMID: 20974809; PubMed Central PMCID: PMC3019847.

27: Elshamy WM. Induction of breast cancer in wild type p53 cells by BRCA1-IRIS overexpression. Hawaii Med J. 2010 Aug;69(8):200-1. PubMed PMID: 20845286; PubMed Central PMCID: PMC3118025.

28: Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, Shaw DP, Ma L, Brown A, Hoffman T, Rold TL, Atasoy U. Overexpression of the RNA binding protein HuRim pairs tumor growth in triple negative breast cancer associated with deficient
angiogenesis. Cell Cycle. 2010 Aug 15;9(16):3337-46. doi: 10.4161/cc.9.16.12711. Epub 2010 Aug 17. PubMed PMID: 20724828; PubMed Central PMCID: PMC3041167.

29: Yuan Z, Sanders AJ, Ye L, Jiang WG. HuR, a key post-transcriptional regulator, and its implication in progression of breast cancer. Histol Histopathol. 2010 Oct;25(10):1331-40. Review. PubMed PMID: 20712017.

30: Xu F, Zhang X, Lei Y, Liu X, Liu Z, Tong T, Wang W. Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. J Cell Biochem. 2010 Oct 15;111(3):727-34. doi: 10.1002/jcb.22762.
PubMed PMID: 20626035.

31: Chock K, Allison JM, Elshamy WM. BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells. Oncogene.2010 Sep 23;29(38):5274-85. doi: 10.1038/onc.2010.262. Epub 2010 Jul 12. PubMed PMID: 20622893.

32: Calaluce R, Gubin MM, Davis JW, Magee JD, Chen J, Kuwano Y, Gorospe M, Atasoy U. The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer. BMC Cancer. 2010  Apr 6;10:126. doi: 10.1186/1471-2407-10-126. PubMed PMID: 20370918;
PubMed Central PMCID: PMC2856550.

33: Blume SW, Jackson NL, Frost AR, Grizzle WE, Shcherbakov OD, Choi H, Meng Z. Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological
activation of the IGF1R IRES. Exp Mol Pathol. 2010 Jun;88(3):341-52. doi: 10.1016/j.yexmp.2010.03.006. Epub 2010 Mar 15. PubMed PMID: 20233590; PubMed Central PMCID: PMC2868104.

34: Guo X, Wu Y, Hartley RS. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol. 2009 Nov-Dec;6(5):575-83. PubMed PMID: 19875930; PubMed Central PMCID: PMC3645467.

35: Guo X, Wu Y, Hartley RS. Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer. Mol Carcinog. 2010 Feb;49(2):130-40. doi: 10.1002/mc.20582. PubMed PMID: 19777567; PubMed Central
PMCID: PMC2813375.

36: Licata LA, Hostetter CL, Crismale J, Sheth A, Keen JC. The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines. Breast Cancer Res Treat. 2010 Jul;122(1):55-63. doi: 10.1007/s10549-009-0517-8.
Epub 2009 Sep 2. PubMed PMID: 19728080.

37: Lim SJ, Lee SH, Joo SH, Song JY, Choi SI. Cytoplasmic expression of HuR is related to cyclooxygenase-2 expression in colon cancer. Cancer Res Treat. 2009 Jun;41(2):87-92. doi: 10.4143/crt.2009.41.2.87. Epub 2009 Jun 30. PubMed PMID:
19707506; PubMed Central PMCID: PMC2731207.

38: Strimpakos AS, Syrigos KN, Saif MW. Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP. 2009 Jul 6;10(4):357-60. PubMed PMID: 19581734.

39: Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res. 2009 Jun
15;69(12):5168-76. doi: 10.1158/0008-5472.CAN-08-4238. Epub 2009 Jun 2. PubMed PMID: 19491267; PubMed Central PMCID: PMC2724875.

40: Woo HH, Zhou Y, Yi X, David CL, Zheng W, Gilmore-Hebert M, Kluger HM, Ulukus EC, Baker T, Stoffer JB, Chambers SK. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene.
2009 Mar 5;28(9):1176-86. doi: 10.1038/onc.2008.469. Epub 2009 Jan 19. PubMed PMID: 19151756.

41: Hostetter CL, Licata LA, Keen JC. Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. Cancer Lett. 2009 Mar 18;275(2):178-84. doi: 10.1016/j.canlet.2008.10.005. Epub 2008 Nov 13. PubMed PMID: 19013015.

42: Saunus JM, French JD, Edwards SL, Beveridge DJ, Hatchell EC, Wagner SA, Stein SR, Davidson A, Simpson KJ, Francis GD, Leedman PJ, Brown MA. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding
protein HuR. Cancer Res. 2008 Nov 15;68(22):9469-78. doi: 10.1158/0008-5472.CAN-08-1159. PubMed PMID: 19010922.

43: Yoo PS, Sullivan CA, Kiang S, Gao W, Uchio EM, Chung GG, Cha CH. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol. 2009 Jan;16(1):200-7.
doi: 10.1245/s10434-008-0209-3. Epub 2008 Nov 14. PubMed PMID: 19009247.

44: Mazan-Mamczarz K, Hagner PR, Dai B, Wood WH, Zhang Y, Becker KG, Liu Z, Gartenhaus RB. Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach. Cancer Res. 2008 Oct
1;68(19):7730-5. doi: 10.1158/0008-5472.CAN-08-2393. PubMed PMID: 18829526; PubMed Central PMCID: PMC2692251.

45: Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, Brody JR, Keen JC. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer
Biol Ther. 2008 Sep;7(9):1496-506. Epub 2008 Sep 23. PubMed PMID: 18769129.

46: Ortega AD, Sala S, Espinosa E, González-Barón M, Cuezva JM. HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. Carcinogenesis.
2008 Nov;29(11):2053-61. doi: 10.1093/carcin/bgn185. Epub 2008 Aug 6. PubMed PMID: 18687667.

47: Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schäfer S, Jung M, Benz CC. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res. 2008
Jul;6(7):1250-8. doi: 10.1158/1541-7786.MCR-07-2110. PubMed PMID: 18644987; PubMed Central PMCID: PMC2583372.

48: Mazan-Mamczarz K, Hagner PR, Corl S, Srikantan S, Wood WH, Becker KG, Gorospe M, Keene JD, Levenson AS, Gartenhaus RB. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene. 2008 Oct 16;27(47):6151-63. doi: 10.1038/onc.2008.215. Epub 2008 Jul 21. PubMed PMID: 18641687; PubMed Central PMCID: PMC2575016.

49: Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomäki K, Blomqvist C,  Heikkilä P, Haglund C, Nevanlinna H, Ristimäki A. Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res. 2007 Dec 1;13(23):6959-63. PubMed
PMID: 18056170.

50: Pryzbylkowski P, Obajimi O, Keen JC. Trichostatin A and 5 Aza-2'deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res Treat. 2008 Sep;111(1):15-25. Epub
2007 Sep 21. PubMed PMID: 17891453.

51: López de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol. 2005 Jan;2(1):11-3. Epub 2005 Jan 19. PubMed PMID:17132932.

52: Leandersson K, Riesbeck K, Andersson T. Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. Nucleic Acids Res. 2006;34(14):3988-99. Epub 2006 Aug 12. PubMed PMID: 16914445; PubMed Central
PMCID: PMC1557823.

53: Guo X, Hartley RS. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res. 2006 Aug 15;66(16):7948-56. PubMed PMID: 16912169.

54: Sommer S, Cui Y, Brewer G, Fuqua SA. The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells. J Steroid Biochem Mol Biol. 2005 Nov;97(3):219-29. PubMed PMID: 16289864.

55: Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, Ristimäki A. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 2005 Mar 15;65(6):2157-61. PubMed
PMID: 15781626.

56: Suswam EA, Nabors LB, Huang Y, Yang X, King PH. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer. 2005 Mar 1;113(6):911-9. PubMed PMID: 15514971.

57: Denkert C, Weichert W, Winzer KJ, Müller BM, Noske A, Niesporek S, Kristiansen G, Guski H, Dietel M, Hauptmann S. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2
expression in human breast carcinoma. Clin Cancer Res. 2004 Aug 15;10(16):5580-6.PubMed PMID: 15328200.

58: Giles KM, Daly JM, Beveridge DJ, Thomson AM, Voon DC, Furneaux HM, Jazayeri JA, Leedman PJ. The 3'-untranslated region of p21WAF1 mRNA is a  cis-acting sequence bound by RNA-binding proteins from breast cancer cells,
including HuR and poly(C)-binding protein. J Biol Chem. 2003 Jan 31;278(5):2937-46. Epub 2002 Nov 12. PubMed PMID: 12431987.

59: Yeap BB, Voon DC, Vivian JP, McCulloch RK, Thomson AM, Giles KM, Czyzyk-Krzeska MF, Furneaux H, Wilce MC, Wilce JA, Leedman PJ. Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3'-untranslated region of the androgen receptor messenger RNA. J Biol Chem. 2002 Jul 26;277(30):27183-92. Epub 2002 May 13. PubMed PMID: 12011088